Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

NCT05393427 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05393427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05393427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 15, 2022
Completion date
December 31, 2025
Enrollment
4 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urinary tumors, other solid tumors